SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Mangalam Drugs And Organics Ltd (MANGALAM) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

BSE: 532637 NSE: MANGALAM | Pharmaceuticals & Drugs | Small Cap

Mangalam Drugs&Org. Share Price

29.50 0.00 (0.00%)
As on 07-May'26 11:57

Mangalam Drugs And Organics Ltd (MANGALAM)

BSE: 532637 NSE: MANGALAM
Key Metrics
Market Cap
₹47 Cr.
P/E Ratio
0.00
Price to Book (P/B)
0.40
Price to Sales (P/S)
0.20
EV/EBITDA
77.89
Return on Capital Employed (ROCE)
8.40%
Current Price
₹29.5
Return on Equity (ROE)
4.76%
Return on Assets (ROA)
1.93%
Operating Profit Margin
11.4%
Net Profit Margin
2.18%
Gross Profit Margin
6.7%
Book Value per Share
₹74.3
Sales Growth (YoY)
-13.66%
Sales Growth (3 Years)
-10.98%
Operating Profit Growth (1 Year)
105.98%
Operating Profit Growth (3 Years)
-9.96%
Net Profit Growth (1 Year)
NA%
52-Week Low / High
₹23 / 95
Net Profit Growth (3 Years)
-29.38%
Dividend Yield
0.00%
Promoter Holding
35.65%
Pledged shares (%)
of Promoter's holding (%)
0.00%

Check Before You Invest

Q.1 Stock return of Mangalam Drugs And Organics Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of -18.3% based on the current price.
Q.1 Revenue growth of Mangalam Drugs And Organics Ltd?
Mangalam Drugs And Organics Ltd revenue growth is -13.7% for FY-2025, which is below its 5-year CAGR of 2.42%, indicating slower growth.
Q.1 Which industry/sub-sector does Mangalam Drugs And Organics Ltd belong to?
Mangalam Drugs And Organics Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.1 Promoter shareholding and pledge status of Mangalam Drugs And Organics Ltd?
Promoters hold 35.65% of the Mangalam Drugs And Organics Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1 Revenue growth of Mangalam Drugs And Organics Ltd vs industry peers?
Mangalam Drugs And Organics Ltd revenue CAGR is 2.42%, compared to the industry median CAGR of 8.30%, indicating slower growth and losing its market share.

DeciZen - make an informed investing decision on Mangalam Drugs&Org.

Based on:

M-Cap below 100cr DeciZen not available

Mangalam Drugs And Organics stock performance

Key Ratios
mw4me loader

Is Mangalam Drugs And Organics Ltd an attractive stock to invest in?

1. Is Mangalam Drugs And Organics Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Mangalam Drugs And Organics Ltd is a average quality company.

2. Is Mangalam Drugs And Organics Ltd undervalued or overvalued?

The key valuation ratios of Mangalam Drugs And Organics Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone.

3. Is Mangalam Drugs And Organics Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Mangalam Drugs And Organics Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray :

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Mangalam Drugs And Organics Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 29.1%30.2%25.4%1.8%10.7%28%18.3%6.7%1.2%8.4%-
Value Creation
Index
1.11.20.8-0.9-0.21.00.3-0.5-0.9-0.4-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 295303279228282385451372369318238
Sales YoY Gr.-2.7%-7.8%-18.5%24.1%36.3%17.3%-17.5%-1%-13.7%-
Adj EPS 11.214.512.3-5.15.217.712.40.8-5.74.3-19.3
YoY Gr.-29.3%-15.4%-141.6%NA240.5%-29.9%-93.5%-811.3%NA-
BVPS (₹) 36.954.265.660.465.782.695.19689.993.974.3
Adj Net
Profit
16.22319.4-8.18.22819.61.3-96.9-31
Cash Flow from Ops. 21.842.824.621.730.627.625.738.112.242.8-
Debt/CF from Ops. 2.71.52.82.91.62.33.127.82.1-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 0.9%2.4%-11%-13.7%
Adj EPS -10%-3.5%-29.5%NA
BVPS10.9%7.4%-0.4%4.4%
Share Price -18.3% -26.1% -36% -59.4%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
35.531.220.5-8.18.223.813.90.8-6.14.7-23
Op. Profit
Mgn %
12.815.516.84.38.415.110.96.94.711.40.6
Net Profit
Mgn %
5.57.67-3.62.97.34.30.3-2.52.2-12.9
Debt to
Equity
1.10.80.70.70.50.50.50.50.70.6-
Working Cap
Days
130114130162136126131192201229131
Cash Conv.
Cycle
565862834748699570820

Recent Performance Summary

Debt to equity has declined versus last 3 years average to 0.59

Return on Equity is Poor

Sales growth has been subdued in last 3 years -10.98%

Sales growth is not so good in last 4 quarters at -31.53%

Latest Financials

Standalone Consolidated
TTM EPS (₹) -19.3 -19.5
TTM Sales (₹ Cr.) 238 238
BVPS (₹) 74.3 69.9
Reserves (₹ Cr.) 102 95
P/BV 0.40 0.42
PE 0.00 0.00
From the Market
52 Week Low / High (₹) 22.70 / 94.80
All Time Low / High (₹) 3.43 / 441.50
Market Cap (₹ Cr.) 46.7
Equity (₹ Cr.) 15.8
Face Value (₹) 10
Industry PE 44.8

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *18.0817.5814.8810.2611.0113.2313.2334.587.090.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Mangalam Drugs&Org. - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales295.02302.89279.38227.58282.35384.70451.07372.25368.59318.23
Operating Expenses + 257.50256.97232.53217.90258.66326.68402.01346.53351.22282.43
Manufacturing Costs22.3823.0229.1526.6024.0130.1741.9945.3250.3055.25
Material Costs203.92195.94166.77153.61195.35251.96306.64250.44244.51167.37
Employee Cost 14.3919.0822.9825.8226.0429.8837.2534.6139.0740.59
Other Costs 16.8118.9313.6311.8713.2514.6716.1416.1517.3419.23
Operating Profit 37.5245.9246.859.6823.6958.0249.0525.7217.3835.80
Operating Profit Margin (%) 12.7%15.2%16.8%4.3%8.4%15.1%10.9%6.9%4.7%11.3%
Other Income + 0.200.310.840.321.1800.090.440.120.50
Exceptional Items 0000000000
Interest 9.2910.0411.788.6510.409.3311.1612.9613.9214.93
Depreciation 4.415.016.577.098.229.1810.2510.9914.6316.38
Profit Before Tax 24.0231.1829.35-5.746.2539.5227.732.21-11.064.99
Tax 7.988.919.462.29-211.558.080.94-2.01-1.93
Profit After Tax 16.0322.2819.89-8.038.2527.9719.661.27-9.056.92
PAT Margin (%) 5.4%7.4%7.1%-3.5%2.9%7.3%4.4%0.3%-2.5%2.2%
Adjusted EPS (₹)11.214.112.6-5.15.217.712.40.8-5.74.4
Dividend Payout Ratio (%)0%0%4%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund + 53.0485.72103.7795.66103.94130.79150.56151.96142.35148.66
Share Capital 14.3815.8315.8315.8315.8315.8315.8315.8315.8315.83
Reserves 38.6669.8987.9479.8388.11114.96134.73136.13126.52132.83
Debt +52.3058.1761.9059.1146.0358.0672.2068.3387.9581.17
Long Term Debt16.9216.8511.158.604.176.8825.1018.7713.359.23
Short Term Debt35.3841.3250.7550.5141.8651.1847.1049.5774.6071.94
Minority Interest0000000000
Trade Payables20.6820.7837.6332.4156.5943.3954.5595.4383.0591.32
Others Liabilities 33.7524.8423.5024.1724.1031.8751.1242.2743.7938.10
Total Liabilities 159.76189.50226.79211.36230.67264.11328.43357.98357.14359.24

Fixed Assets

Net Fixed Assets +54.1992.56101.91103.49101.07117.82134.96142.36147.31155.52
Gross Block97.57140.26156.14165.15170.92196.70223.81241.40260.69280.14
Accumulated Depreciation43.3847.7054.2361.6669.8578.8888.8599.04113.38124.62
CWIP 4.9300.070.201.246.355.719.497.742.69
Investments 0.241.640.240.240.220.22000.030.03
Inventories47.3437.2560.1373.4564.8458.59117.11137.47123.64138.80
Trade Receivables30.1436.8245.2117.6339.9854.3146.4946.5327.9439.07
Cash Equivalents 0.500.630.431.431.630.591.951.041.012.57
Others Assets 22.4320.6118.7914.9121.6826.2222.2021.0949.4820.54
Total Assets 159.76189.50226.79211.36230.67264.11328.43357.98357.14359.24

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity + 21.8142.8024.5821.6930.5527.5525.7138.0812.1742.76
PBT 24.0231.1829.35-5.746.2539.5227.732.21-11.064.99
Adjustment 13.8517.4518.3016.2218.7117.2422.3724.1227.8130.37
Changes in Working Capital -12.111.5-16.8111.215.64-19.94-15.5911.72-4.397.49
Tax Paid -3.95-7.33-6.260-0.05-9.27-8.810.03-0.19-0.08
Cash Flow From Investing Activity + -10.88-39.45-15.95-9.26-6.87-31.29-27.33-22.17-17.91-19.47
Capex -10.91-39.46-15.98-9.28-6.89-31.29-27.53-22.17-17.88-19.47
Net Investments 0-00.0100.0200.210-0.030
Others 0.020.020.020.02000000
Cash Flow From Financing Activity + -11.11-3.22-8.82-11.43-23.482.702.98-16.825.70-21.71
Net Proceeds from Shares 00.9400000000
Net Proceeds from Borrowing -21.65-0.07-5.70-2.55-4.422.7018.23-6.34-5.41-4.12
Interest Paid -9.29-10.04-11.76-8.65-10.40-9.33-11.16-12.96-13.92-14.93
Dividend Paid 00-0.790000000
Others 19.835.949.43-0.24-8.659.32-4.092.4725.03-2.66
Net Cash Flow -0.180.13-0.2010.20-1.041.36-0.91-0.041.57

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)38.9132.1120.99-8.058.2723.8313.970.84-6.154.76
ROCE (%)29.1430.1825.351.7610.6628.0118.346.651.238.4
Asset Turnover Ratio1.841.791.481.181.421.561.521.081.030.89
PAT to CFO Conversion(x)1.361.921.24N/A3.70.981.3129.98N/A6.18
Working Capital Days
Receivable Days44.8039.1048.7044.3033.6044.7040.8045.6036.9038.40
Inventory Days6349.4057.8094.2080.6058.6071.10124.80129.30150.50
Payable Days67.5038.6063.9083.2083.2072.4058.30109.30133.20190.10

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Mangalam Drugs And Organics Ltd FAQs

The current trading price of Mangalam Drugs&Org. on 07-May-2026 11:57 is ₹29.50.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 06-May-2026 the market cap of Mangalam Drugs&Org. stood at ₹46.69 Cr

The latest P/E ratio of Mangalam Drugs&Org. as of 06-May-2026 is 0.00.

The latest P/B ratio of Mangalam Drugs&Org. as of 06-May-2026 is 0.40.

The 52-week high of Mangalam Drugs&Org. is ₹94.80 and the 52-week low is ₹22.70.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Mangalam Drugs&Org. is ₹238 ( Cr.) .

About Mangalam Drugs And Organics Ltd

Mangalam Drugs & Organics Limited (Mangalam) is a part of the MangalamGroup promoted by Dhoot family in 1972 as Advent Pharma PrivateLimited with a view to set up a plant for manufacture of organic andinorganic chemicals. Mangalam Drugs & Organics commmenced its business in 1977.

The company manufactures chemicals such as API perfumery, disperse dye intermediates, bulk drugs and bulk drugs intermediates at VAPI-Gujarat State. It has a multi-product manufacturing facility and a in-house Research and Development (R&D) Base.

The Company has a diversified product range having synergies in operations and substantial economies of scale. It is amongst the top three manufacturers in India in almost all the products that it manufactures.

Today Mangalam Drugs & Organics enjoys a very strong brand name in the domestic market. It has over two decades of experience in the industry with a very wide and satisfied customer base.

The company has a state of art multi-product manufacturing facilitiesat Vapi in Gujarat and Sangamner in Maharashtra for production of bulkdrugs perfumery chemicals inorganic chemicals and disperse dyesintermediaries with a strong in-house Research and Development base.

Product range of the company includes:

Active Pharma Ingredients (API)

  • Anti Malarial
  • Analgesic / Anti Inflammatory
  • Diuretic
  • Anti Hypertensive
  • Anti Convulsant

API Under Development

  • Intermediates
  • Antiurolithic

Prefumery / Specialty Chemicals

  • Phenyl Ethyl Alcohol
  • Phenyl Ethyl Methyl Ether
  • Phenyl Ethyl Acetate

Disperse Dye Intermediates

  • Meta Nitro Aniline (Mna)(99-09-2)
  • Meta Amino Propionilide (MAP)
  • Meta Amino Acetanilide (MAA) (162-28-3)
  • Para Amino Acetanilide (PAA) 122-80-5)
  • Para Amino Propionilide (PAP) (59690-89-0)
  • N-Cyano Ethyl Aniline (1075-76-9)
  • N,N-BIS (2-Hydroxy Ethyl) Meta Chloro Aniline (Mangalam-1) (92-00-2)
  • N,N-BIS (2-Acetoxy Ethyl) Meta Chloro Aniline (Mangalam -1A) (26692-46-6) etc.

Achievements/ recognition:

  • Awarded the ISO 9001:2000 Management System Certificate from DNV for Design Development, Manufacture and supply of Bulk Drugs, and Dyes Intermediates.
  • Received the WHO GMP Certificate for its Bulk Drug manufacturing Plant
You have 0 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×